Form 8-K Edwards Lifesciences For: Jul 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Edwards Lifesciences (EW) shares decline as growth disappoints investors
July 27, 2023 12:19 PM EDTShares of Edwards Lifesciences (NYSE: EW) declined after it reported second quarter results. Despite solid earnings per share and revenue, growth rates disappointed investors.
Edwards Lifesciences reported second quarter sales that were slightly above consensus at $1.53 billion. At $0.66, EPS topped consensus by a penny.
The company expects full year 2023 sales to be between $5.9 billion and $6.1 billion. For the year, the company expects transcatheter aortic... More
